<DOC>
	<DOCNO>NCT00248612</DOCNO>
	<brief_summary>The propose project write `` typical clinical practice '' test fully-controlled trial combine anxiety-focused CBT pharmacotherapy ( venlafaxine ; CBT-VEN ) deliver patient comorbid alcohol-use anxiety disorder . The CBT pharmacotherapy contrast relaxation training placebo medication . One hundred eighty participant recruit , subsequent platform outpatient treatment alcoholism , randomly assign 12-week treatment condition . All treatment condition begin 1-week placebo run-in , participant begin trial venlafaxine placebo . The treatment conclude 2-week medication/placebo taper . Follow-up assessment conduct post-treatment 3 , 6 , 9 , 12-months . The long-term objective research develop real-world combination psychosocial pharmacological treatment patient comorbid alcohol-use anxiety disorder compromise prognosis , evaluate effectiveness combine psychosocial pharmacological treatment target anxiety among patient comorbidity .</brief_summary>
	<brief_title>Psychosocial Medication Treatment Anxiety Alcoholism</brief_title>
	<detailed_description>Difficulties anxiety management frequent cause relapse alcohol use . Empirical data support role anxiety alcohol relapse , psychosocial pharmacological treatment alcohol problem increasingly address role negative affect alcohol-use disorder . Due lack large , well-controlled treatment outcome trial , optimal treatment ( combination treatment ) remain unknown . Real world practice treatment alcohol-use disorder frequently begin brief detoxification stabilization , often follow combination CBT pharmacotherapy patient complain mood difficulty attempt early abstinence alcohol . The purpose present study evaluate relative benefit psychosocial psychopharmacological therapy treatment co-morbid anxiety alcohol dependence among patient attempt early abstinence alcohol . We address follow four question : 1 . During course intervention , treatment anxiety disorder combine treatment establish utility ( among non-alcohol-use-disordered patient ) superior manage return drink anxiety symptom either monotherapy , fully inactive control treatment ? 2 . During follow-up period , patient receive combined active treatment fare well maintain abstinence relative single active treatment , control condition ? 3 . What psychosocial variable ( increase lapse elevated anxiety ) mediate return pre-treatment level alcohol use ? 4 . Will baseline index alcohol dependence anxiety disorder severity moderate relationship treatment outcome acute follow-up phase study ?</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol-Related Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Participants must Englishspeaking male female Participants must 18 65 year old Meet criterion DSMIV diagnosis alcohol abuse dependence Meet criterion Panic disorder , Social Phobia Generalized Anxiety Disorder Physically able attend session Counseling Center Able read write Able complete structure interview selfreport assessment packet Able attend treatment session followup assessment Able sign witness informed consent form Participants express desire completely stop drinking alcohol reduce alcohol consumption possible longterm goal abstinence Meet DSMIV diagnostic criterion bipolar disorder , schizophrenia , bulimia/anorexia , dementia Currently take anticraving agent ( e.g . Naltrexone , methadone ) Currently take medication clinically significant interaction venlafaxine Previous use venlafaxine Currently take antidepressant medication Currently take medication know decrease anxiety alcohol consumption ( e.g . antabuse ) Currently prescribe medication know abuse potential ( e.g. , subject opioid agonist therapy ) Currently prescribe medication sleep aid ( e.g . Ambien ) Currently take herbal supplement show interact venlafaxine affect anxiety symptom Currently pregnant , breastfeed , plan become pregnant course study , use medically acceptable form birth control ( oral contraceptive , barrier [ diaphragm condom ] spermicide , intrauterine progesterone contraceptive system , levonorgestrel implant , medroxyprogesterone acetate contraceptive injection ) . Planning relocate outofstate within four month protocol initiation History psychotic symptom within past 30 day Experiencing severe symptom depression engage suicidal behavior within past 30 day Medical contraindication use venlafaxine [ severe renal disease , cirrhosis , uncontrolled blood pressure , recent cardiovascular problem ( e.g. , heart attack ) , seizure disorder ; currently take monoamine oxidase inhibitor , MAOI ] Selfreported anxiety le 15 Hamilton Rating Scale Anxiety Participant member household another subject already participate study Participant legally mandate ( e.g. , avoid incarceration , monetary penalty , etc . ) participate alcohol treatment program Participant current recent ( past 30 day ) DSMIV diagnosis substance abuse dependence , exception nicotine , marijuana , caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Venlafaxine</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Anxiety Disorders</keyword>
	<keyword>Alcohol-Use Disorders</keyword>
	<keyword>Alcohol Abuse</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Cognitive Behavioral Treatment</keyword>
</DOC>